Acute myelogenous leukemia infection

The current induction therapy for acute myelogenous leukemia (AML) usually consists of a combination of cytara-bine and daunorubicin, with the frequent addition of a steroid and/or an antimetabolite such as 6-thioguanine. The risk of infection is so high during this period that patients receive antibiotic and fungal prophylaxis. 

H. Other considerations Leukine has been designated an orphan product for use in the treatment of neutropenia associated with bone marrow transplantation, leukemia, graft failure and delay of engraft-ment, promotion of early engraftment, and to decrease the incidence of death due to infection in patients with acute myelogenous leukemia. 

Klehn, T.E., Polsky, B., Punithalingam, E., Edwards, F.F., Brown, A.E., Armstrong, D. Liver infection caused by Coniothyrium fuckelii in a patient with acute myelogenous leukemia. J. Chn. Microbiol. 1987 25 2410-2412... 

Clinical trials are still few. Several of the earliest reported to date are only from the early 1990s. To illustrate, a treatment trial on genital warts induced by papilloma virus was reported (Anonymous A, 1993). An AIDS infection trial (Anonymous B, 1993) and an acute myelogenous leukemia test (Anonymous C, 1993) are also in the literature. 

---